Effect of homologous or heterologous vaccine booster over two initial doses of inactivated COVID-19 vaccine

References

• Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–733. doi: 10.1056/NEJMoa2001017
   PubMed Web of Science ®Google Scholar
• Li YD, Chi WY, Su JH, et al. Coronavirus vaccine development: from SARS and MERS to COVID-19. J Biomed Sci. 2020;27(1):104. doi: 10.1186/s12929-020-00695-2
   PubMed Web of Science ®Google Scholar
• Li X, Yang X, Ning Z. Efficacy and safety of COVID-19 inactivated vaccine: a meta-analysis. Front Med. 2022;9:1015184. doi: 10.3389/fmed.2022.1015184
   Google Scholar
• Zhuang C, Liu X, Chen Q, et al. Protection duration of COVID-19 vaccines: waning effectiveness and future perspective. Front Microbiol. 2022;13:828806. doi: 10.3389/fmicb.2022.828806
   PubMed Web of Science ®Google Scholar
• Costa Clemens SA, Weckx L, Clemens R, et al. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. Lancet. 2022;399(10324):521–529. doi: 10.1016/S0140-6736(22)00094-0
   PubMed Web of Science ®Google Scholar
• Zhang X, Xia J, Jin L, et al. Effectiveness of homologous or heterologous immunization regimens against SARS-CoV-2 after two doses of inactivated COVID-19 vaccine: a systematic review and meta-analysis. Hum Vaccin Immunother. 2023;19(2):2221146. doi: 10.1080/21645515.2023.2221146
   PubMed Web of Science ®Google Scholar
• Tanriover MD, Doganay HL, Akova M, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021;398(10296):213–222. doi: 10.1016/S0140-6736(21)01429-X
   PubMed Web of Science ®Google Scholar
• Jara A, Undurraga EA, Gonzalez C, et al. Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile. N Engl J Med. 2021;385(10):875–884. doi: 10.1056/NEJMoa2107715
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21(2):181–192. doi: 10.1016/S1473-3099(20)30843-4
   PubMed Web of Science ®Google Scholar
• Al Kaabi N, Zhang Y, Xia S, et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA. 2021;326(1):35–45. doi: 10.1001/jama.2021.8565
   PubMed Web of Science ®Google Scholar
• Al Kaabi N, Oulhaj A, Ganesan S, et al. Effectiveness of BBIBP-CorV vaccine against severe outcomes of COVID-19 in Abu Dhabi, United Arab Emirates. Nat Commun. 2022;13(1):3215. doi: 10.1038/s41467-022-30835-1
   PubMed Web of Science ®Google Scholar
• Xia S, Zhang Y, Wang Y, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2021;21(1):39–51. doi: 10.1016/S1473-3099(20)30831-8
   PubMed Web of Science ®Google Scholar
• Ella R, Reddy S, Jogdand H, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial. Lancet Infect Dis. 2021;21(7):950–961. doi: 10.1016/S1473-3099(21)00070-0
   PubMed Web of Science ®Google Scholar
• Ella R, Reddy S, Blackwelder W, et al. Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial. Lancet. 2021;398(10317):2173–2184. doi: 10.1016/S0140-6736(21)02000-6
   PubMed Web of Science ®Google Scholar
• Lazarus R, Querton B, Corbic Ramljak I, et al. Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial. Lancet Infect Dis. 2022;22(12):1716–1727. doi: 10.1016/S1473-3099(22)00502-3
   PubMed Web of Science ®Google Scholar
• Ozdarendeli A, Sezer Z, Pavel STI, et al. Safety and immunogenicity of an inactivated whole virion SARS-CoV-2 vaccine, TURKOVAC, in healthy adults: interim results from randomised, double-blind, placebo-controlled phase 1 and 2 trials. Vaccine. 2023;41(2):380–390. doi: 10.1016/j.vaccine.2022.10.093
   PubMed Web of Science ®Google Scholar
• Tanriover MD, Aydin OA, Guner R, et al. Efficacy, immunogenicity, and safety of the two-dose schedules of TURKOVAC versus CoronaVac in healthy subjects: a randomized, observer-blinded, non-inferiority phase III trial. Vaccines (Basel). 2022;10(11):1865. doi: 10.3390/vaccines10111865
   PubMed Web of Science ®Google Scholar
• Khairullin B, Zakarya K, Orynbayev M, et al. Efficacy and safety of an inactivated whole-virion vaccine against COVID-19, QazCovid-in(R), in healthy adults: a multicentre, randomised, single-blind, placebo-controlled phase 3 clinical trial with a 6-month follow-up. EClinicalMedicine. 2022;50:101526. doi: 10.1016/j.eclinm.2022.101526
   PubMedGoogle Scholar
• Barchuk A, Bulina A, Cherkashin M, et al. Gam-COVID-Vac, EpiVacCorona, and CoviVac effectiveness against lung injury during Delta and Omicron variant surges in St. Petersburg, Russia: a test-negative case-control study. Respir Res. 2022;23(1):276. doi: 10.1186/s12931-022-02206-3
   PubMed Web of Science ®Google Scholar
• Ishmukhametov AA, Siniugina AA, Yagovkina NV, et al. Safety and immunogenicity of inactivated whole virion vaccine CoviVac against COVID-19: a 2 multicenter, randomized, double-blind, placebo-controlled phase I/II clinical trial. medRxiv. 2022.
   Google Scholar
• Liu J, Huang B, Li G, et al. Immunogenicity and safety of a 3-dose regimen of a SARS-CoV-2 inactivated vaccine in adults: a randomized, double-blind, placebo-controlled phase 2 trial. J Infect Dis. 2022;225(10):1701–1709. doi: 10.1093/infdis/jiab627
   PubMed Web of Science ®Google Scholar
• Mohraz M, Salehi M, Tabarsi P, et al. Safety and immunogenicity of an inactivated virus particle vaccine for SARS-CoV-2, BIV1-CovIran: findings from double-blind, randomised, placebo-controlled, phase I and II clinical trials among healthy adults. BMJ Open. 2022;12(4):e056872. doi: 10.1136/bmjopen-2021-056872
   PubMedGoogle Scholar
• Pitisuttithum P, Luvira V, Lawpoolsri S, et al. Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: interim results of a randomised, placebo-controlled, phase 1 trial. EClinicalMedicine. 2022;45:101323. doi: 10.1016/j.eclinm.2022.101323
   PubMedGoogle Scholar
• Dadras O, Mehraeen E, Karimi A, et al. Safety and Adverse Events Related to Inactivated COVID-19 Vaccines and Novavax;a Systematic Review. Arch Acad Emerg Med. 2022;10(1):e54. doi: 10.3390/vaccines10030482
   PubMedGoogle Scholar
• Devi K, Ali N, Nasir N, et al. VITT with inactivated SARS-CoV-2 vaccine - index case. Hum Vaccin Immunother. 2022;18(1):2036556. doi:10.1080/21645515.2022.2036556
   PubMed Web of Science ®Google Scholar
• Hosseinzadeh R, Barary M, Mehdinezhad H, et al. Thrombotic thrombocytopenia after sinopharm BBIBP-CorV COVID-19 vaccination. Res Pract Thromb Haemost. 2022;6(4):e12750. doi: 10.1002/rth2.12750
   PubMed Web of Science ®Google Scholar
• Kim AY, Woo W, Yon DK, et al. Thrombosis patterns and clinical outcome of COVID-19 vaccine-induced immune thrombotic thrombocytopenia: a systematic review and meta-analysis. Int J Infect Dis. 2022;119:130–139. doi: 10.1016/j.ijid.2022.03.034
   PubMed Web of Science ®Google Scholar
• Lai FTT, Li X, Peng K, et al. Carditis after COVID-19 vaccination with a Messenger RNA vaccine and an inactivated virus vaccine: a case-control study. Ann Intern Med. 2022;175(3):362–370. doi: 10.7326/M21-3700
   PubMed Web of Science ®Google Scholar
• Ella R, Vadrevu KM, Jogdand H, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. Lancet Infect Dis. 2021;21(5):637–646. doi: 10.1016/S1473-3099(20)30942-7
   PubMed Web of Science ®Google Scholar
• Peng Q, Zhou R, Wang Y, et al. Waning immune responses against SARS-CoV-2 variants of concern among vaccinees in Hong Kong. EBioMedicine. 2022;77:103904. doi: 10.1016/j.ebiom.2022.103904
   PubMed Web of Science ®Google Scholar
• Zhu Y, Yang X, Xun J, et al. Neutralization of five SARS-CoV-2 variants of concern by convalescent and BBIBP-CorV vaccinee serum. Virol Sin. 2022;37(6):831–841. doi: 10.1016/j.virs.2022.10.006
   PubMed Web of Science ®Google Scholar
• Vikkurthi R, Ansari A, Pai AR, et al. Inactivated whole-virion vaccine BBV152/Covaxin elicits robust cellular immune memory to SARS-CoV-2 and variants of concern. Nat Microbiol. 2022;7(7):974–985. doi: 10.1038/s41564-022-01161-5
   PubMed Web of Science ®Google Scholar
• NP K, VV B, CPG K, et al. Inactivated COVID-19 vaccines: durability of Covaxin/BBV152 induced immunity against variants of concern. J Travel Med. 2022;29(6). doi: 10.1093/jtm/taac088
   Web of Science ®Google Scholar
• Mok CKP, Cohen CA, Cheng SMS, et al. Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID-19 vaccines in Hong Kong. Respirology. 2022;27(4):301–310. doi: 10.1111/resp.14191
   PubMed Web of Science ®Google Scholar
• Petrovic V, Vukovic V, Patic A, et al. Immunogenicity of BNT162b2, BBIBP-CorV and Gam-COVID-Vac vaccines and immunity after natural SARS-CoV-2 infection—A comparative study from novi sad, Serbia. PLoS One. 2022;17(2):e0263468. doi: 10.1371/journal.pone.0263468
   PubMed Web of Science ®Google Scholar
• Fadlyana E, Rusmil K, Tarigan R, et al. A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: an interim analysis in Indonesia. Vaccine. 2021;39(44):6520–6528. doi: 10.1016/j.vaccine.2021.09.052
   PubMed Web of Science ®Google Scholar
• Desai D, Khan AR, Soneja M, et al. Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study. Lancet Infect Dis. 2022;22(3):349–356. doi: 10.1016/S1473-3099(21)00674-5
   PubMed Web of Science ®Google Scholar
• Li J, Hou L, Guo X, et al. Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial. Nat Med. 2022;28(2):401–409. doi: 10.1038/s41591-021-01677-z
   PubMed Web of Science ®Google Scholar
• Acevedo J, Acevedo ML, Gaete-Argel A, et al. Neutralizing antibodies induced by homologous and heterologous boosters in CoronaVac vaccines in Chile. Clin Microbiol Infect. 2023;29(4):e541 541–e541 547. doi: 10.1016/j.cmi.2022.11.017
   Web of Science ®Google Scholar
• Ai J, Zhang H, Zhang Y, et al. Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost. Emerg Microbes Infect. 2022;11(1):337–343. doi: 10.1080/22221751.2021.2022440
   PubMed Web of Science ®Google Scholar
• Zhang Y, Ma X, Yan G, et al. Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: a randomised, double-blinded, placebo-controlled, phase 2 trial. EClinicalMedicine. 2022;54:101680. doi: 10.1016/j.eclinm.2022.101680
   PubMedGoogle Scholar
• Mallah SI, Alawadhi A, Jawad J, et al. Safety and efficacy of COVID-19 prime-boost vaccinations: homologous BBIBP-CorV versus heterologous BNT162b2 boosters in BBIBP-CorV-primed individuals. Vaccine. 2023;41(12):1925–1933. doi: 10.1016/j.vaccine.2023.01.032
   PubMed Web of Science ®Google Scholar
• Angkasekwinai N, Niyomnaitham S, Sewatanon J, et al. The immunogenicity and reactogenicity of four COVID-19 booster vaccinations against SARS-CoV-2 variants following CoronaVac or ChAdOx1 nCoV-19 primary series. Asian Pac J Allergy Immunol. 2023. doi: 10.12932/AP-160123-1533
   PubMedGoogle Scholar
• Jin PF, Guo XL, Gou JB, et al. Immunogenicity and safety of heterologous immunisation with Ad5-nCOV in healthy adults aged 60 years and older primed with an inactivated SARS-CoV-2 vaccine (CoronaVac): a phase 4, randomised, observer-blind, non-inferiority trial. Lancet Reg Health West Pac. 2023;100829:100829. doi: 10.1016/j.lanwpc.2023.100829
   Google Scholar
• Roa CC, de Los Reyes MRA, Plennevaux E, et al. Superior boosting of neutralizing titers against omicron SARS-CoV-2 variants by heterologous SCB-2019 vaccine vs a homologous booster in CoronaVac-primed adults. J Infect Dis. 2023;228(9):1253–1262. doi: 10.1093/infdis/jiad262
   PubMed Web of Science ®Google Scholar
• Kaabi NA, Yang YK, Zhang J, et al. Immunogenicity and safety of NVSI-06-07 as a heterologous booster after priming with BBIBP-CorV: a phase 2 trial. Signal Transduct Target Ther. 2022;7(1):172. doi: 10.1038/s41392-022-00984-2
   PubMed Web of Science ®Google Scholar
• Assawakosri S, Kanokudom S, Suntronwong N, et al. Neutralizing activities against the Omicron variant after a heterologous booster in healthy adults receiving two doses of CoronaVac vaccination. J Infect Dis. 2022;226(8):1372–1381. doi: 10.1093/infdis/jiac092
   PubMed Web of Science ®Google Scholar
• Cheng SMS, Mok CKP, Leung YWY, et al. Neutralizing antibodies against the SARS-CoV-2 omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination. Nat Med. 2022;28(3):486–489. doi: 10.1038/s41591-022-01704-7
   PubMed Web of Science ®Google Scholar
• Kuloglu ZE, El R, Guney-Esken G, et al. Effect of BTN162b2 and CoronaVac boosters on humoral and cellular immunity of individuals previously fully vaccinated with CoronaVac against SARS-CoV-2: a longitudinal study. Allergy. 2022;77(8):2459–2467. doi: 10.1111/all.15316
   PubMed Web of Science ®Google Scholar
• Zeng G, Wu Q, Pan H, et al. Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials. Lancet Infect Dis. 2022;22(4):483–495. doi: 10.1016/S1473-3099(21)00681-2
   PubMed Web of Science ®Google Scholar
• Niyomnaitham S, Jongkaewwattana A, Meesing A, et al. Immunogenicity of a fractional or full third dose of AZD1222 vaccine or BNT162b2 messenger RNA vaccine after two doses of CoronaVac vaccines against the Delta and Omicron variants. Int J Infect Dis. 2023;129:19–31. doi: 10.1016/j.ijid.2023.01.022
   PubMed Web of Science ®Google Scholar
• Muangnoicharoen S, Wiangcharoen R, Nanthapisal S, et al. Single Ad26.COV2.S booster dose following two doses of BBIBP-CorV vaccine against SARS-CoV-2 infection in adults: day 28 results of a phase 1/2 open-label trial. Vaccine. 2023;41(32):4648–4657. doi: 10.1016/j.vaccine.2023.06.043
   PubMed Web of Science ®Google Scholar
• Al Kaabi N, Yang Y, Eldin Hussein S, et al. Efficacy and safety of a booster vaccination with two inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: results of a double-blind, randomized, placebo-controlled, phase 3 trial in Abu Dhabi. Vaccines (Basel). 2023;11(2):299. doi: 10.3390/vaccines11020299
   PubMed Web of Science ®Google Scholar
• Schultz BM, Melo-Gonzalez F, Duarte LF, et al. A booster dose of CoronaVac Increases Neutralizing Antibodies and T Cells that Recognize Delta and omicron variants of concern. MBio. 2022;13(4):e0142322. doi: 10.1128/mbio.01423-22
   PubMed Web of Science ®Google Scholar
• Kulkarni PS, Gunale B, Kohli S, et al. A phase 3, randomized, non-inferiority study of a heterologous booster dose of SARS CoV-2 recombinant spike protein vaccine in adults. Sci Rep. 2023;13(1):16579. doi: 10.1038/s41598-023-43578-w
   PubMed Web of Science ®Google Scholar
• Nanthapisal S, Puthanakit T, Jaru-Ampornpan P, et al. A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines. Vaccine. 2022;40(18):2551–2560. doi: 10.1016/j.vaccine.2022.03.036
   PubMed Web of Science ®Google Scholar
• Jara A, Undurraga EA, Zubizarreta JR, et al. Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study. Lancet Glob Health. 2022;10(6):e798–e806. doi: 10.1016/S2214-109X(22)00112-7
   PubMed Web of Science ®Google Scholar
• Zeng T, Lu Y, Zhao Y, et al. Effectiveness of the booster dose of inactivated COVID-19 vaccine against omicron BA.5 infection: a matched cohort study of adult close contacts. Respir Res. 2023;24(1):246. doi: 10.1186/s12931-023-02542-y
   PubMed Web of Science ®Google Scholar
• Menegale F, Manica M, Zardini A, et al. Evaluation of waning of SARS-CoV-2 vaccine-induced immunity: a systematic review and meta-analysis. JAMA Netw Open. 2023;6(5):e2310650. doi: 10.1001/jamanetworkopen.2023.10650
   PubMed Web of Science ®Google Scholar
• Khong KW, Zhang R, Hung IF. The four ws of the fourth dose COVID-19 vaccines: why, who, when and what. Vaccines (Basel). 2022;10(11):1924. doi: 10.3390/vaccines10111924
   PubMed Web of Science ®Google Scholar
• Goldberg Y, Mandel M, Bar-On YM, et al. Protection and waning of natural and hybrid immunity to SARS-CoV-2. N Engl J Med. 2022;386(23):2201–2212. doi: 10.1056/NEJMoa2118946
   PubMed Web of Science ®Google Scholar
• Regev-Yochay G, Gonen T, Gilboa M, et al. Efficacy of a fourth dose of covid-19 mRNA vaccine against omicron. N Engl J Med. 2022;386(14):1377–1380. doi: 10.1056/NEJMc2202542
   PubMed Web of Science ®Google Scholar
• Arbel R, Sergienko R, Friger M, et al. Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years. Nat Med. 2022;28(7):1486–1490. doi: 10.1038/s41591-022-01832-0
   PubMed Web of Science ®Google Scholar
• Mendez C, Penaloza HF, Schultz BM, et al. Humoral and cellular response induced by a second booster of an inactivated SARS-CoV-2 vaccine in adults. EBioMedicine. 2023;91:104563. doi: 10.1016/j.ebiom.2023.104563
   PubMed Web of Science ®Google Scholar
• Wang J, Deng C, Liu M, et al. A fourth dose of the inactivated SARS-CoV-2 vaccine redistributes humoral immunity to the N-terminal domain. Nat Commun. 2022;13(1):6866. doi: 10.1038/s41467-022-34633-7
   PubMed Web of Science ®Google Scholar
• World Health Organisation. SAGE updates COVID-19 vaccination guidance. (2023)
   Google Scholar
• Duc Dang A, Dinh Vu T, Hai Vu H, et al. Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: interim results of a randomized, placebo-controlled, phase 1/2 trial in Vietnam. Vaccine. 2022;40(26):3621–3632. doi: 10.1016/j.vaccine.2022.04.078
   PubMed Web of Science ®Google Scholar
• Blom K, Marking U, Havervall S, et al. Immune responses after omicron infection in triple-vaccinated health-care workers with and without previous SARS-CoV-2 infection. Lancet Infect Dis. 2022;22(7):943–945. doi: 10.1016/S1473-3099(22)00362-0
   PubMed Web of Science ®Google Scholar